Demographic characteristics of donors
| Characteristic . | PBSC donors n (%) . | BM donors n (%) . | P value . |
|---|---|---|---|
| No. of donors | 14 530 | 7123 | |
| No. of filgrastim exposures, n (%) | |||
| 1 | 13 579 (93) | N/A | |
| 2 | 416 (3) | N/A | |
| 3 | 6 (<1) | N/A | |
| No. of BM donations, n (%) | |||
| 1 | N/A | 6496 (91) | |
| 2 | N/A | 169 (2) | |
| 3 | N/A | 12 (<1) | |
| No. of both BM donations and filgrastim exposures∗ , n (%) | .846 | ||
| 1 BM donation,1 filgrastim exposure | 498 (3) | 416 (6) | |
| 1 BM donation, 2 filgrastim exposures | 13 (<1) | 12 (<1) | |
| 2 BM donations, 1 filgrastim exposure | 18 (<1) | 18 (<1) | |
| Sex, n (%) | .019 | ||
| Female | 5975 (41) | 3048 (43) | |
| Male | 8 555 (59) | 4075 (57) | |
| Race, n (%) | <.001 | ||
| White | 10 980 (76) | 5070 (71) | |
| Hispanic | 1 252 (9) | 798 (11) | |
| Black | 498 (3) | 396 (6) | |
| Asian/Pacific Islander | 800 (6) | 407 (6) | |
| Native American | 103 (1) | 68 (1) | |
| Multiple races/other | 848 (6) | 360 (5) | |
| Unknown/decline | 49 (<1) | 24 (<1) | |
| Age at first BM collection or first filgrastim injection, y, n (%) | <.001 | ||
| Median (min-max) | 33 (18-62) | 35 (19-61) | <.001 |
| 18-29 | 5 896 (41) | 2542 (36) | |
| 30-39 | 3 871 (27) | 2186 (31) | |
| 40-49 | 3 231 (22) | 1804 (25) | |
| 50+ | 1 532 (11) | 591 (8) | |
| Year of first BM collection or first filgrastim injection, n (%) | <.001 | ||
| 1989 | 0 | 1 (<1) | |
| 1990 | 0 | 4 (<1) | |
| 1991 | 0 | 3 (<1) | |
| 1992 | 0 | 7 (<1) | |
| 1993 | 0 | 19 (<1) | |
| 1994 | 0 | 9 (<1) | |
| 1995 | 0 | 10 (<1) | |
| 1996 | 0 | 25 (<1) | |
| 1997 | 0 | 30 <1) | |
| 1998 | 0 | 36 (1) | |
| 1999 | 15 (<1) | 281 (4) | |
| 2000 | 137 (1) | 492 (7) | |
| 2001 | 195 (1) | 435 (6) | |
| 2002 | 317 (2) | 457 (6) | |
| 2003 | 466 (3) | 375 (5) | |
| 2004 | 453 (3) | 307 (4) | |
| 2005 | 537 (4) | 243 (3) | |
| 2006 | 587 (4) | 272 (4) | |
| 2007 | 652 (4) | 276 (4) | |
| 2008 | 777 (5) | 280 (4) | |
| 2009 | 850 (6) | 297 (4) | |
| 2010 | 1 001 (7) | 329 (5) | |
| 2011 | 1 450 (10) | 510 (7) | |
| 2012 | 1 772 (12) | 656 (9) | |
| 2013 | 2 010 (14) | 656 (9) | |
| 2014 | 1 817 (13) | 625 (9) | |
| 2015 | 1 479 (10) | 484 (7) | |
| 2016 | 15 (<1) | 4 (<1) | |
| Median (min-max) follow-up, y | 7.0 (0.6-20.2) | 9.0 (0.0-29.2) | <.001 |
| Characteristic . | PBSC donors n (%) . | BM donors n (%) . | P value . |
|---|---|---|---|
| No. of donors | 14 530 | 7123 | |
| No. of filgrastim exposures, n (%) | |||
| 1 | 13 579 (93) | N/A | |
| 2 | 416 (3) | N/A | |
| 3 | 6 (<1) | N/A | |
| No. of BM donations, n (%) | |||
| 1 | N/A | 6496 (91) | |
| 2 | N/A | 169 (2) | |
| 3 | N/A | 12 (<1) | |
| No. of both BM donations and filgrastim exposures∗ , n (%) | .846 | ||
| 1 BM donation,1 filgrastim exposure | 498 (3) | 416 (6) | |
| 1 BM donation, 2 filgrastim exposures | 13 (<1) | 12 (<1) | |
| 2 BM donations, 1 filgrastim exposure | 18 (<1) | 18 (<1) | |
| Sex, n (%) | .019 | ||
| Female | 5975 (41) | 3048 (43) | |
| Male | 8 555 (59) | 4075 (57) | |
| Race, n (%) | <.001 | ||
| White | 10 980 (76) | 5070 (71) | |
| Hispanic | 1 252 (9) | 798 (11) | |
| Black | 498 (3) | 396 (6) | |
| Asian/Pacific Islander | 800 (6) | 407 (6) | |
| Native American | 103 (1) | 68 (1) | |
| Multiple races/other | 848 (6) | 360 (5) | |
| Unknown/decline | 49 (<1) | 24 (<1) | |
| Age at first BM collection or first filgrastim injection, y, n (%) | <.001 | ||
| Median (min-max) | 33 (18-62) | 35 (19-61) | <.001 |
| 18-29 | 5 896 (41) | 2542 (36) | |
| 30-39 | 3 871 (27) | 2186 (31) | |
| 40-49 | 3 231 (22) | 1804 (25) | |
| 50+ | 1 532 (11) | 591 (8) | |
| Year of first BM collection or first filgrastim injection, n (%) | <.001 | ||
| 1989 | 0 | 1 (<1) | |
| 1990 | 0 | 4 (<1) | |
| 1991 | 0 | 3 (<1) | |
| 1992 | 0 | 7 (<1) | |
| 1993 | 0 | 19 (<1) | |
| 1994 | 0 | 9 (<1) | |
| 1995 | 0 | 10 (<1) | |
| 1996 | 0 | 25 (<1) | |
| 1997 | 0 | 30 <1) | |
| 1998 | 0 | 36 (1) | |
| 1999 | 15 (<1) | 281 (4) | |
| 2000 | 137 (1) | 492 (7) | |
| 2001 | 195 (1) | 435 (6) | |
| 2002 | 317 (2) | 457 (6) | |
| 2003 | 466 (3) | 375 (5) | |
| 2004 | 453 (3) | 307 (4) | |
| 2005 | 537 (4) | 243 (3) | |
| 2006 | 587 (4) | 272 (4) | |
| 2007 | 652 (4) | 276 (4) | |
| 2008 | 777 (5) | 280 (4) | |
| 2009 | 850 (6) | 297 (4) | |
| 2010 | 1 001 (7) | 329 (5) | |
| 2011 | 1 450 (10) | 510 (7) | |
| 2012 | 1 772 (12) | 656 (9) | |
| 2013 | 2 010 (14) | 656 (9) | |
| 2014 | 1 817 (13) | 625 (9) | |
| 2015 | 1 479 (10) | 484 (7) | |
| 2016 | 15 (<1) | 4 (<1) | |
| Median (min-max) follow-up, y | 7.0 (0.6-20.2) | 9.0 (0.0-29.2) | <.001 |
N/A, not applicable; min, minimum; max, maximum; y, years.
Donors in the BM group who later had exposure to filgrastim were censored at the time of filgrastim exposure.